The anti-CRISPR protein (red on right) mimics DNA, binding in the site where the cutting enzyme Cas9 typically grips the target DNA (left) before it cuts. But the anti-CRISPR protein doesn't let ...

A federal appeals court said the patent office made legal errors in awarding foundational patents for CRISPR-Cas9 to the ...

An order from a federal appeals court has kicked the battle wide open again over who holds the key patents for CRISPR-Cas9, a ...

The University of Bayreuth's Biomaterials research group has, for the first time, successfully applied the CRISPR-Cas9 ...

Cas9, the first Cas protein repurposed for cutting DNA, introduces double-strand breaks that recruit DNA repair machinery. Despite its successes, the CRISPR-Cas9 system has several limitations, ...

CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

“We have demonstrated, for the first time worldwide, that CRISPR-Cas9 can be used to incorporate a desired sequence into ...

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

The study applied a new approach that installed hairpin internal nuclear localization signal sequences (hiNLS) at selected sites within the backbone of CRISPR-Cas9. This approach contrasts with ...

"Our study is a first step in dramatically expanding our repertoire of effective and safe CRISPR-Cas9 enzymes. In our manuscript, we demonstrate the utility of these PAMmla-predicted enzymes to ...